eli lilly glp 1 oral tirzepatide to seek approval of new GLP-1 weight-loss drug this year FDA says shortage of GLP-1 Founday (orforglipron), the new oral

It does not make compounded medications equivalent to FDA-approved products

With the emergence of therapies targeting CHEs underlying immunopathogenesis, a shift towards a pragmatic, prompt, and patient-centered approach is warranted

Larsen also noted that Marty Makary, M.D., President Donald Trump's pick to lead the FDA, will have "influence over the enforcement of semaglutide compounding and personalization efforts." Makary is an executive at Sesame, another telehealth company that connects consumers with physicians to prescribe compounded weight loss drugs

36.2 million people with ESI are potentially eligible for GLP-1 drugs based on an obesity diagnosis alone